EVP-ABD-enhanced MRI to evaluate diffuse liver disease in a rat model

✍ Scribed by Chun S. Zuo; Peter R. Seoane; Morgane Thomsen; Tim Gillis; Edward Meloni; Phillip P. Harnish; Perry F. Renshaw

• Publisher: John Wiley and Sons
• Year: 2008
• Tongue: English
• Weight: 228 KB
• Volume: 27
• Category: Article
• ISSN: 1053-1807
• DOI: 10.1002/jmri.21385

✦ Synopsis

Abstract

Purpose

To evaluate the feasibility of using manganese‐based MR imaging contrast agent EVP‐ABD to detect diffuse liver disease in an established rat hepatitis model.

Materials and Methods

Hepatitis was induced by administration of CCl~4~ in corn oil vehicle to rats intraperitoneally. MR images were acquired on a 3T scanner using a volume coil ≈36 hours after the administration of CCl~4~. EVP‐ABD was administered via a tail vein at a dose of 10 μmol/kg. Multi‐TI turboflash images were acquired to evaluate liver R1 (=1/T1) values before and after the EVP‐ABD administration. Eighteen rats received various doses of CCl~4~ and completed pre‐ and postcontrast MRI scans and liver histologic evaluation.

Results

The liver R1 after the EVP‐ABD administration and the change of the liver R1 before and after the administration, ΔR1, show significant correlations with the CCl~4~ dose. A significant correlation was also found between the histologic scores and the CCl~4~ doses despite known variability in the relationship of CCl~4~ dose to histology. A significant correlation was found between the histologic score and ΔR1.

Conclusion

Our results indicate that EVP‐ABD‐enhanced MRI can detect diffuse liver disease generated by CCl~4~ based on the significant correlation between proton R1 in liver following EVP‐ABD and the CCl~4~ doses as well as the histologic scores. J. Magn. Reson. Imaging 2008;27:1317–1321. © 2008 Wiley‐Liss, Inc.